Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Takashi Fukagai is a leading figure in urologic oncology, with a research focus centered on prostate cancer epidemiology, surgical outcomes, and health economics. He is a key architect of the Asian Prostate Cancer (A-CaP) study, a landmark Asia-wide initiative launched in 2015 that systematically surveys treatment patterns and patient outcomes across the continent—a foundational contribution to understanding regional disparities in prostate cancer care (12 citations). Dr. Fukagai has also advanced the evidence base for minimally invasive surgery. Using a Japanese nationwide database, he conducted a pivotal comparative analysis of in-hospital fees and surgical outcomes for robot-assisted, laparoscopic, and open radical cystectomy, providing crucial data for cost-conscious clinical decision-making (5 citations). Most recently, his work on preoperative predictors of seminal vesicle invasion (pT3b) in robot-assisted radical prostatectomy aims to refine surgical planning and reduce unexpected stage upgrades (1 citation). Through these efforts, Dr. Fukagai has shaped both regional practice guidelines and the global conversation on surgical value and precision in urologic oncology.